The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis.
The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis. Mucosal Immunol. 2018 09; 11(5):1454-1465.